162 related articles for article (PubMed ID: 12553555)
21. CD30 ligand in lymphoma patients with CD30+ tumors.
Younes A; Consoli U; Snell V; Clodi K; Kliche KO; Palmer JL; Gruss HJ; Armitage R; Thomas EK; Cabanillas F; Andreeff M
J Clin Oncol; 1997 Nov; 15(11):3355-62. PubMed ID: 9363866
[TBL] [Abstract][Full Text] [Related]
22. Nitrotyrosine, inducible nitric oxide synthase (iNOS), and endothelial nitric oxide synthase (eNOS) are increased in thyroid tumors from children and adolescents.
Patel A; Fenton C; Terrell R; Powers PA; Dinauer C; Tuttle RM; Francis GL
J Endocrinol Invest; 2002 Sep; 25(8):675-83. PubMed ID: 12240898
[TBL] [Abstract][Full Text] [Related]
23. Regulation of murine B cell growth and differentiation by CD30 ligand.
Shanebeck KD; Maliszewski CR; Kennedy MK; Picha KS; Smith CA; Goodwin RG; Grabstein KH
Eur J Immunol; 1995 Aug; 25(8):2147-53. PubMed ID: 7664777
[TBL] [Abstract][Full Text] [Related]
24. Pancreas cancer-associated antigen (PCAA) in medullary thyroid carcinoma.
Ueno K; Kobayashi T; Shimano T; Matsuura N; Monden T; Takeda T; Tomita N; Mori T
Med J Osaka Univ; 1994 Sep; 43(1-4):17-21. PubMed ID: 7609706
[TBL] [Abstract][Full Text] [Related]
25. Proliferation of CD30+ T-helper 2 lymphoma cells can be inhibited by CD30 receptor cross-linking with recombinant CD30 ligand.
Willers J; Dummer R; Kempf W; Kündig T; Burg G; Kadin ME
Clin Cancer Res; 2003 Jul; 9(7):2744-54. PubMed ID: 12855655
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical demonstration of thyrotropin (TSH)-receptor in normal and diseased human thyroid tissues using monoclonal antibody against recombinant human TSH-receptor protein.
Mizukami Y; Hashimoto T; Nonomura A; Michigishi T; Nakamura S; Noguchi M; Matsukawa S
J Clin Endocrinol Metab; 1994 Aug; 79(2):616-9. PubMed ID: 8045985
[TBL] [Abstract][Full Text] [Related]
27. Thyroid cytology and the risk of malignancy in thyroid nodules: importance of nuclear atypia in indeterminate specimens.
Kelman AS; Rathan A; Leibowitz J; Burstein DE; Haber RS
Thyroid; 2001 Mar; 11(3):271-7. PubMed ID: 11327619
[TBL] [Abstract][Full Text] [Related]
28. Expression of Pax-8, p53 and bcl-2 in human benign and malignant thyroid diseases.
Puglisi F; Cesselli D; Damante G; Pellizzari L; Beltrami CA; Di Loreto C
Anticancer Res; 2000; 20(1A):311-6. PubMed ID: 10769673
[TBL] [Abstract][Full Text] [Related]
29. [Expression of E-cadherin in thyroid neoplastic tissues and its correlation with malignant and metastatic potential].
Naitoh A; Kobayashi S; Iwase H; Kuzushima T
Nihon Rinsho; 1995 Jul; 53(7):1619-22. PubMed ID: 7629998
[TBL] [Abstract][Full Text] [Related]
30. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid.
Soh EY; Duh QY; Sobhi SA; Young DM; Epstein HD; Wong MG; Garcia YK; Min YD; Grossman RF; Siperstein AE; Clark OH
J Clin Endocrinol Metab; 1997 Nov; 82(11):3741-7. PubMed ID: 9360534
[TBL] [Abstract][Full Text] [Related]
31. Blood group antigens in differentiated thyroid neoplasms.
González-Cámpora R; García-Sanatana JA; Jordà i Heras MM; Salaverri CO; Vázquez-Ramírez FJ; Argueta-Manzano OE; Galera-Davidson H
Arch Pathol Lab Med; 1998 Nov; 122(11):957-65. PubMed ID: 9822123
[TBL] [Abstract][Full Text] [Related]
32. Determination of galectin-3 messenger ribonucleic Acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction.
Bernet VJ; Anderson J; Vaishnav Y; Solomon B; Adair CF; Saji M; Burman KD; Burch HB; Ringel MD
J Clin Endocrinol Metab; 2002 Oct; 87(10):4792-6. PubMed ID: 12364475
[TBL] [Abstract][Full Text] [Related]
33. Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases.
Oflazoglu E; Grewal IS; Gerber H
Adv Exp Med Biol; 2009; 647():174-85. PubMed ID: 19760074
[TBL] [Abstract][Full Text] [Related]
34. CITED1 protein expression suggests Papillary Thyroid Carcinoma in high throughput tissue microarray-based study.
Prasad ML; Pellegata NS; Kloos RT; Barbacioru C; Huang Y; de la Chapelle A
Thyroid; 2004 Mar; 14(3):169-75. PubMed ID: 15072698
[TBL] [Abstract][Full Text] [Related]
35. Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies.
Buergy D; Weber T; Maurer GD; Mudduluru G; Medved F; Leupold JH; Brauckhoff M; Post S; Dralle H; Allgayer H
Int J Cancer; 2009 Aug; 125(4):894-901. PubMed ID: 19480010
[TBL] [Abstract][Full Text] [Related]
36. Autoimmune thyroiditis in benign and malignant thyroid nodules: 16-year results.
Giagourta I; Evangelopoulou C; Papaioannou G; Kassi G; Zapanti E; Prokopiou M; Papapostolou K; Karga H
Head Neck; 2014 Apr; 36(4):531-5. PubMed ID: 23729390
[TBL] [Abstract][Full Text] [Related]
37. [Expression of cytokeratin19, galectin-3 and HBME-1 in thyroid lesions and their differential diagnoses].
Teng XD; Wang LJ; Yao HT; Li J; Ding W; Yan LP
Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):212-6. PubMed ID: 15256110
[TBL] [Abstract][Full Text] [Related]
38. CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin.
Gattei V; Degan M; Gloghini A; De Iuliis A; Improta S; Rossi FM; Aldinucci D; Perin V; Serraino D; Babare R; Zagonel V; Gruss HJ; Carbone A; Pinto A
Blood; 1997 Mar; 89(6):2048-59. PubMed ID: 9058727
[TBL] [Abstract][Full Text] [Related]
39. Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells.
Gruss HJ; Ulrich D; Braddy S; Armitage RJ; Dower SK
Eur J Immunol; 1995 Jul; 25(7):2083-9. PubMed ID: 7621881
[TBL] [Abstract][Full Text] [Related]
40. Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease.
Molin D; Fischer M; Xiang Z; Larsson U; Harvima I; Venge P; Nilsson K; Sundström C; Enblad G; Nilsson G
Br J Haematol; 2001 Sep; 114(3):616-23. PubMed ID: 11552987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
